267 related articles for article (PubMed ID: 35788962)
1. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
[TBL] [Abstract][Full Text] [Related]
2. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
3. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
Petersen CL; Hougaard A; Gaist D; Hallas J
JAMA Neurol; 2024 Mar; 81(3):248-254. PubMed ID: 38315477
[TBL] [Abstract][Full Text] [Related]
4. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS
Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476
[TBL] [Abstract][Full Text] [Related]
5. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
[TBL] [Abstract][Full Text] [Related]
6. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice.
Hall GC; Brown MM; Mo J; MacRae KD
Neurology; 2004 Feb; 62(4):563-8. PubMed ID: 14981171
[TBL] [Abstract][Full Text] [Related]
7. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
[TBL] [Abstract][Full Text] [Related]
8. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
[TBL] [Abstract][Full Text] [Related]
9. Acute Migraine Prescription Patterns Vary by Baseline Cardiovascular Risk and Clinical Characteristics: A Real-World Evidence Study.
Li H; Vincent M; Zhang X; Dennehy EB; Goodloe R; Aurora SK; Smith TR
Pain Ther; 2020 Dec; 9(2):499-509. PubMed ID: 32328974
[TBL] [Abstract][Full Text] [Related]
10. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
11. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
12. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
13. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
Roberto G; Raschi E; Piccinni C; Conti V; Vignatelli L; D'Alessandro R; De Ponti F; Poluzzi E
Cephalalgia; 2015 Feb; 35(2):118-31. PubMed ID: 25246519
[TBL] [Abstract][Full Text] [Related]
14. Acute migraine treatment with oral triptans and NSAIDs in a managed care population.
Ng-Mak DS; Hu XH; Chen YT; Ma L
Headache; 2008 Sep; 48(8):1176-85. PubMed ID: 18819177
[TBL] [Abstract][Full Text] [Related]
15. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
16. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
17. Triptan use as a function of cardiovascular risk. A population-based study.
Bigal ME; Golden W; Buse D; Chen YT; Lipton RB
Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953
[TBL] [Abstract][Full Text] [Related]
18. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
19. Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
Hyeraci G; Gini R; Bezin J; Iannone LF; Benemei S; Lupi C; De Cesaris F; Geppetti P; Roberto G
Headache; 2023 Feb; 63(2):222-232. PubMed ID: 36705316
[TBL] [Abstract][Full Text] [Related]
20. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
